Jun 14, 2022 4:30pm EDT

Nexera Schedules Fourth Quarter and Fiscal Year 2022 Conference Call

Jun 06, 2022 8:30am EDT

Treosulfan Pivotal Study Results Published

May 24, 2022 5:05pm EDT

Nexera Pharmaceuticals Provides Update on Resubmission of Treosulfan NDA

Apr 22, 2022 8:30am EDT

Nexera Pharmaceuticals Announces Resubmission of Treosulfan NDA

Apr 19, 2022 4:20pm EDT

Nexera to Present at the Bloom Burton & Co. Healthcare Investor Conference

Mar 09, 2022 8:00am EST

Nexera to Participate in the 34th Annual Roth Conference

Mar 01, 2022 7:15am EST

Nexera Pharmaceuticals Announces Deal for Gleolan in the United States

Feb 14, 2022 8:00am EST

Nexera Pharmaceuticals Announces Normal Course Issuer Bid, or NCIB, for Convertible Debentures

Feb 09, 2022 6:30pm EST

Nexera Pharmaceuticals Generated $21.3M in Fiscal 2022 Third Quarter Revenues and Achieved $1.9M Positive EBITDA for the Three Months Ended December 31, 2021

Feb 01, 2022 4:15pm EST

Nexera to Present at The MicroCap Rodeo’s 2nd Annual Winter Wonderland Best Ideas Investor Conference